tbuckley/cabot-search huggingface dataset:
53 Unique insights into PDAC development revealed by both InSituPlex® and imaging mass cytometry
Authors: Andrew Quong, Mark Rees, Kirsteen Maclean, Mael Manesse, Jordan Nieto, Amanda Esch, Devan Fleury, Keith Wharton, Gourab Chatterjee
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Pancreatic cancer remains a deadly disease due to difficulties hindering its early diagnosis, giving way to metastasis of the tumor and resulting in poor prognosis. While there are many neoplasms of the pancreas, pancreatic invasive ductal adenocarcinoma (PDAC) is the most common and treatment options are few, with poor overall survival. Aggressive surgeries such as the Whipple procedure coupled to systemic chemotherapy is one of the few treatment options. Recently, several publications have demonstrated improved outcomes with the inclusion of immunotherapy to cytotoxic drug combinations in some patients, however optimally selecting patients as candidates for immunotherapy-chemotherapy combinations remains a critical challenge. The complexities of the tumor microenvironment have been implicated in the failure of chemotherapy, radiation therapy, and immunotherapy. The tumor microenvironment of PDAC is especially rich with multiple interactions between pancreatic epithelial/cancer cells, stromal cells, immune cells and the extracellular matrix (ECM). PDACs are characterized by a complex ECM of desmoplastic reaction consisting of an extensive and dense fibrotic stroma that surrounds and infiltrates clusters of malignant epithelial cells, together with the loss of basement membrane integrity and an abnormal vasculature. Methods In the present study we demonstrate a tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. This novel translational workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high dimensional imaging in selected regions of interest (ROI), by combining H&amp;E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry (IMC™). Results The use of the InSituPlex® UltiMapper® I/O PD-L1 kit enabled the streamlined combination and alignment of H&amp;E and mIF data, leading to the strategic selection of relevant ROIs, while utility of IMC technology enabled downstream imaging of 35 protein markers associated with the ECM in the selected ROIs to provide a deeper understanding of the tumor microenvironment. Conclusions The incorporation of advanced multiplex imaging platforms such as mIF and IMC with routine H&amp;E workflow in tumor biology can deliver some of the much-needed insight into tumor morphology, cellular composition, cellular functions, and cell-cell interactions and paves the way for potentially improved clinical prognosis and efficacy prediction in patients with cancer.
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy
Authors: Matteo Ravaioli, Quirino Lai, Maurizio Sessa, Davide Ghinolfi, Guido Fallani, Damiano Patrono, Stefano Di Sandro, Alfonso Avolio, Federica Odaldi, Jessica Bronzoni, Francesco Tandoi, Riccardo De Carlis, Marco Maria Pascale, Gianluca Mennini, Giuliana Germinario, Massimo Rossi, Salvatore Agnes, Luciano De Carlis, Matteo Cescon, Renato Romagnoli, Paolo De Simone
Journal: Journal of Hepatology (2021)
Re-Print- COVID-19 Cardiac Complications: Is an Easy, Safe treatment Strategy Right under Our Noses?
Authors: Gary L Murray
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

Background: Many chronic conditions, as Diabetes Mellitus (DM) and cardiovascular Diseases, suffer Major Adverse Cardiac Events (MACE): congestive heart failure (CHF), Ventricular Tachycardia (VT), Ventricular Fibrillation (VF), Acute Coronary Syndromes [ACSs], and Sudden Cardiac Death (SCD). Acute infections, like COVID-19, also involve oxidative stress, leading to increased Sympathetic tone (S) and decreased Parasympathetic tone (P), increasing Sympathovagal Balance (SB) and MACE. The antioxidant (r) Alpha Lipoic Acid (ALA) improves SB. The antianginal Ranolazine (RAN), also an antioxidant, is an antiarrhythmic. Our studies of their effects on MACE, in DM, and non-DM patients with CHF, ventricular arrhythmias and SCD are reviewed herein, as our findings may apply to acute diseases, such as COVID-19. Methods: (1) In a case-control study, 109 CHF patients, 54 were given adjunctive off-label RAN added to ACC/AHA Guideline therapy (RANCHF). MACE and SB were compared with 55 NORANCHF patients; mean f/u 23.7 mo. (2) 59 adults with triggered premature ventricular contractions (PVCs), bigeminy, and VT were given off-label RAN. Pre- and post-RAN Holters were compared; mean f/u 3.1 mo. (3) 133 DM II with cardiac diabetic autonomic neuropathy were offered (r) ALA; 83 accepted; 50 refused. P&amp;S were followed a mean of 6.31 years, and SCDs recorded. Results: (1) 70% of RANCHF patients increased LVEF 11.3 EFUs (p ≤ 0.003), SCD reduced 56%; VT/VF therapies decreased 53%. (2) 95% of patients responded: VT decreased 91% (p&lt;0.001). (3) SCD was reduced 43% in DM II patients taking (r) ALA (p=0.0076). Conclusion: RAN, (r) ALA treat CHF, VT, and prevent SCD. Trials in COVID-19 are needed.
Single-stranded circular DNA theranostics
Authors: Tingting Shen, Yu Zhang, Lei Mei, Xiao-Bing Zhang, Guizhi Zhu
Journal: Theranostics (2021)

The past decade has witnessed the blossom of nucleic acid therapeutics and diagnostics (theranostics).Unlike conventional small molecule medicines or protein biologics, nucleic acid theranostics have characteristic features such as the intrinsic ability as "information drugs" to code and execute genetic and theranostic information, ready programmability for nucleic acid engineering, intrinsic stimulatory or regulatory immunomodulation, versatile functionalities, and easy conformational recovery upon thermal or chemical denaturation.Single-stranded circular DNA (circDNA) are a class of single-stranded DNAs (ssDNA) featured with their covalently-closed topology.In addition to the basic advantages of nucleic acids-based materials, such as low cost, biocompatibility, and simplicity of chemical modification, the lack of terminals in circDNA prevents exonuclease degradation, resulting in enhanced biostability relative to the corresponding linear ssDNA.circDNA has been explored for versatile theranostic applications.For instance, circDNA has been extensively studied as templates for bioanalytical signal amplification and the synthesis of nano-/micro-/macro-biomaterials via rolling circle amplification (RCA) and rolling circle transcription (RCT) technologies.circDNA has also been commonly used as the scaffolds for the self-assembly of versatile DNA origami.Finally, circDNA has been implemented as theranostic aptamers, miRNA inhibitors, as well as clustered regularly interspaced short palindromic repeats-CRISPR-associated proteins (CRISPR-Cas) gene editing donors.In this review article, we will discuss the chemistry, characteristic properties, and the theranostic applications of circDNA (excluding double-stranded circular DNA such as plasmids); we will also envision the challenges and opportunities in this research field.
Multiomic Single-Cell Sequencing Reveals Patterns of Disease Evolution and Acute Transformation in Chronic Myelomonocytic Leukaemia
Authors: Kristian Gurashi, John Weightman, Syed M Baker, Kevin Rouault-Pierre, Wolfgang Breitweister, Tim C.P Somervaille, Kiran Batta, Daniel H Wiseman
Journal: Blood (2021)
Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Authors: Samuel John, Michael A. Pulsipher, Amy Moskop, Zhen-Huan Hu, Christine L. Phillips, Erin Marie Hall, Steven P. Margossian, Sarah Nikiforow, Paul L. Martin, Benjamin Oshrine, Amy K. Keating, Rayne H. Rouce, Ranjan Tiwari, Santiago Redondo, Jennifer Willert, Abhijit Agarwal, Marcelo C Pasquini, Stephan A. Grupp
Journal: Blood (2021)
TMOD-10. THE ROLE OF IDH1 R132H MUTATION IN GLIOMA – AN INVESTIGATION BY GENOME-EDITING IN HUMAN INDUCED PLURIPOTENT STEM CELLS
Authors: Alexander Köpp, Luzie Gawehn, Doreen William, Matthias Preussler, Susan Richter, Michael Heide, Lara Marrone, Anne Thieme, Felix Kleine Borgmann, Michel Mittelbronn, David Capper, Evelin Schröck, Barbara Klink
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Hot-spot mutations in the Isocitrate dehydrogenase 1 (IDH1) cause a new catalytic function resulting in the production of 2-HG, a hallmark in the development of low-grade glioma. The tumorigenic mechanism of this mutation as well as the cell of origin are not known and there is a lack of suitable disease models. Thus, we aim to create a model mimicking glioma development by introducing the IDH1 R132H into human induced pluripotent stem cells (hiPSC) and investigate the influence on stem cell properties and cell differentiation in neuronal progenitor cells. MATERIAL AND METHODS We use CRISPR/Cas9 based genome editing to induce the IDH1 R132H mutation into healthy-control-derived hiPSCs. Successful introduction of the mutation was confirmed on DNA, RNA and protein level. The hiPSCs are then differentiated into cerebral organoids and characterized using transcriptome sequencing and methylation arrays. RESULTS We successfully introduced the IDH1 R132H mutation into hiPSCs and confirmed expression of the mutated protein by Western Blot. Metabolite measurement using liquid chromatography tandem mass spectrometry (LC-MS/MS) showed a forty times increased concentration of 2-HG in IDH-mutated compared to the wildtype hiPSCs, proving that the mutated enzyme is functional. To investigate effects of IDH1 R132H on cell differentiation, we generated cerebral organoids from our iPSC-models. The IDH1 R132H mutation did not inhibit cell differentiation or maturation of cerebral organoids but led to a downregulation of splicosome, proteasome and DNA repair enzymes as well as an upregulation of ECM components. CONCLUSION AND OUTLOOK hiPSCs with R132H mutation pose a promising model for investigations on early glioma development. We are currently step-wise including TP53 and ATRX loss of function mutations in our hiPSC models to recapitulating tumor development in vivo.
Abstract 9306: Association of Race and Ethnicity and Anticoagulation in Patients With Atrial Fibrillation Dually Enrolled in Va and Medicare: Effects of Medicare Part D on the Equity of Prescribing
Authors: Utibe R Essien, Nadejda Kim, Jared W Magnani, Chester Good, Terrence Litam, Leslie Hausmann, Maria Mor, Walid Gellad, Michael J Fine
Journal: Circulation (2021)

Introduction: Although oral anticoagulation (OAC) remains under-prescribed in racial/ethnic minority patients with atrial fibrillation (AF) managed through the Veterans Health Administration (VA) and Medicare, little is known about how dual VA and Medicare enrollment influences inequities in OAC therapy for AF. Methods: We compared OAC initiation by race/ethnicity in a national cohort of patients with new onset AF (2014-2018) who were dually enrolled in VA and Medicare, with and without Medicare Part D enrollment. Our primary outcome was initiation of any OAC or direct oral anticoagulants (DOAC) within 90 days of an index AF diagnosis. We used mixed effects logistic regression to model the adjusted odds of our outcomes, adjusting for patient, provider, and facility factors and a Medicare Part D by race/ethnicity interaction term. Results: Among 82,353 patients with AF, 53,657 (65.2%) initiated any OAC (65.4% White, 62.5% Black, 65.1% Hispanic); among OAC initiators, 34,473 (64.2%) patients initiated a DOAC (64.9% White, 59.8% Black, 57.0% Hispanic). Compared to White patients, the adjusted odds ratio (aOR) of initiating any OAC was significantly lower for Black (aOR, 0.87; 95% CI 0.82-0.93) but not Hispanic patients (aOR, 1.08; 95% CI 0.97-1.20) ( Figure ). Among OAC initiators, DOAC initiation was significantly lower for Black (aOR, 0.71; 95% CI, 0.65-0.78) and Hispanic (aOR, 0.80; 95% CI, 0.70-0.92) patients. Medicare Part D enrollment did not differentially affect initiating any OAC or DOAC by race/ethnicity (p&gt;.05 for interaction terms in both models). Conclusions: In a national cohort of patients with AF dually enrolled in VA and Medicare, Black patients were less likely to initiate any OAC while DOACs were initiated less in Black and Hispanic vs. White patients. Medicare Part D enrollment did not moderate the associations between race/ethnicity and any OAC or DOAC use suggesting access alone may not be the driver of AF inequities.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Authors: David C W Lau, Lars Erichsen, Ann Marie Francisco, Altynai Satylganova, Carel W le Roux, Barbara McGowan, Sue D Pedersen, Kirsi H Pietiläinen, Domenica Rubino, Rachel L Batterham
Journal: The Lancet (2021)
PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol
Authors: Guy Young, Mark T Reding, Robert F. Sidonio, Doris V. Quon, Janice M. Staber, Cindy A. Leissinger, Jessica Charlet, Moncef Boukerrou
Journal: Blood (2021)
Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021
Authors: Silvia Ciambella, Vincenza Innocenti, Elisa Emanueli Cippitelli, Silvia Bertelli, Roberta Talucci, Valentina Panichi, Giuseppe Topini, Alessia Fiorini, Ambra Di Veroli, Caterina Mercanti, Fiammetta Natalino, Gioia De Angelis, Michela Tarnani, Marco Morucci, Cristina Mastino, Fabio Stagno, Giulio Trapè, Assunta Silvestri, Marco Montanaro, Roberto Latagliata
Journal: Blood (2021)
Increased hnRNP K Expression Impacts Myelopoiesis By Altering <i> RUNX1</i> Splicing
Authors: Sean M Post, Marisa J Aitken, Prerna Malaney, Xiaorui Zhang, Todd Link, Rodrigo Jacamo, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos
Journal: Blood (2021)
Abstract 8962: Meta-Meta-Analysis of Outcomes of Valve-in-Valve TAVI Compared to Redo-SAVR
Authors: Abbas Altamimi, Nida Khan, Surya K Aedma, Karanrajsinh Raol, Abdur Raheem, Shubhi Jain, Sowmya Madireddy, nawal ali, Rizwan Rabbani, Jigisha Rakholiya, Preeti Malik, Urvish K Patel, Suveenkrishna Pothuru
Journal: Circulation (2021)

Introduction: Redo-Surgical valve replacement (Redo-SAVR) is the gold standard treatment for failed degenerated bioprosthetic valves. Recently approved less invasive Valve-In-Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) procedure is becoming more popular but with limited evidence of its safety and efficacy compared to redo-SAVR. Hypothesis: We aimed to conduct the meta-meta analysis to evaluate the outcomes of ViV-TAVI compared to redo-SAVR. Methods: We conducted a systematic search of meta-analysis studies assessing outcomes of ViV-TAVR vs redo-SAVR using PubMed search engine and following PRISMA guidelines from inception to May 2021. A meta-meta-analysis was performed by obtaining a pooled odds ratio, 95% confidence interval (95%CI) using random-effects models to analyze outcomes of 30-day all-cause mortality and procedural mortality. Results: Nine meta-analysis studies were included. We found that there was a significantly lower odds of 30-day all-cause mortality (pooled OR:0.60; 95%CI:0.53-0.68; p&lt;0.00001) with 0% heterogeneity (I2= 0%;p=0.53) in the ViV-TAVI compared to redo-SAVR. We also found a reduced risk of procedural mortality with ViV-TAVI compared to redo-SAVR (pooled OR:0.52; 95%CI:0.27-0.98; p=0.04) with 0% heterogeneity (I2= 0%;p=0.69) (Figure). Conclusions: ViV-TAVI is significantly associated with reduced risk of 30-day all-cause mortality, and procedural mortality compared to redo-SAVR. Our meta-meta-analysis supports that minimally invasive ViV-TAVI is a safe and better procedure for degenerated bioprosthetic valves in high-risk candidates.
Inflammasome-Primed Myeloid Cells Maintain a Pro-Tumor Microenvironment in Multiple Myeloma
Authors: Madelon M.E. de Jong, Cathelijne Fokkema, Natalie Papazian, Sabrin Tahri, Zoltan Kellermayer, Michael Vermeulen, Mark van Duin, Pieter van de Woestijne, Annemiek Broyl, Pieter Sonneveld, Tom Cupedo
Journal: Blood (2021)
Type 1 Calreticulin Mutations Differentially Activate the IRE1α-XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms
Authors: Juan Ibarra, Yassmin Elbanna, Katarzyna Kurylowicz, Harrison S Greenbaum, Maria Evers, Nicole S Arellano, Dongbo Yang, Althea Bock-Hughes, Chenyu Liu, Quinn Smith, Julian Lutze, Julian Baumeister, Milena Kalmer, Kathrin Olschok, Benjamin Nicholson, Diane Silva, Luke Maxwell, Jonathan Dowgielewicz, Michele Ciboddo, Elisa Rumi, Daniela Pietra, Steffen Koschmieder, Sandeep Gurbuxani, Rebekka K. Schneider, Scott Oakes, Shannon Elf
Journal: Blood (2021)
Adhesive anastomosis for organ transplantation
Authors: Kang Liu, Hang Yang, Gaobo Huang, Aihua Shi, Qiang Lu, Shanpei Wang, Wei Qiao, Haohua Wang, Mengyun Ke, Hongfan Ding, Tao Li, Yanchao Zhang, Jiawei Yu, Bingyi Ren, Rongfeng Wang, Kailing Wang, Hui Feng, Zhigang Suo, Jingda Tang, Yi Lv
Journal: Bioactive Materials (2021)

The recent development of tough tissue adhesives has stimulated intense interests among material scientists and medical doctors. However, these adhesives have seldom been tested in clinically demanding surgeries. Here we demonstrate adhesive anastomosis in organ transplantation. Anastomosis is commonly conducted by dense sutures and takes a long time, during which all the vessels are occluded. Prolonged occlusion may damage organs and even cause death. We formulate a tough, biocompatible, bioabsorbable adhesive that can sustain tissue tension and pressurized flow. We expose the endothelial surface of vessels onto a gasket, press two endothelial surfaces to the adhesive using a pair of magnetic rings, and reopen the bloodstream immediately. The time for adhesive anastomosis is shortened compared to the time for sutured anastomosis. We have achieved adhesive anastomosis of a great vein in transplanting the liver of a pig. After the surgery, the adhesive is absorbed, the vein heals, and the pig lives for over one month.
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors
Authors: Srinivas K. Tantravahi, Soo Jin Kim, Divya Sundar, Ami B. Patel, Anthony D. Pomicter, Kenneth M. Boucher, Kamal Chamoun, Jatin Shah, Anton Rets, Tracy I. George, Josef T. Prchal, Michael W. Deininger
Journal: Blood (2021)
Ruxolitinib for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Egor A. Kulagin, Alisa G. Volkova, Anna A. Dotsenko, Valeria R. Yanbukhtina, Julia D. Rabik, Anna G. Smirnova, Irina K. Golubovskaya, Vasiliy I. Trofimov, Ivan S. Moiseev
Journal: Blood (2021)
A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in <i>FLT3</i>-ITD and <i>CBL</i>-Mutant Acute Myeloid Leukemia (PON-AZA study)
Authors: David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei
Journal: Blood (2021)
46 Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC
Authors: Qianyun Luo, Edwin Parra, Marcelo Negrao, Neal Akhave, Erin Bayley, Kyle Mitchell, Jianjun Zhang, John Heymach, Boris Sepesi, Ignacio Wistuba, Don Gibbons, Alexandre Reuben
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background While the development of immunotherapies has improved the treatment of non-small cell lung cancer (NSCLC), most patients still fail to respond. Immune cell densities have been utilized to predict clinical responses but have largely failed to do so. However, the spatial distribution and interaction of these cells at the tissue level have been less studied. Here, we performed spatial analysis of the cells within the tumor immune microenvironment in order to evaluate their relationship with clinical outcomes in early-stage NSCLC. Methods Multiplex immunofluorescence was performed on 123 early-stage NSCLC patients from the ICON (Immunogenomic profiling of non-small cell lung cancer) cohort including Cytokeratin (CK), CD3, CD8, CD45RO, FoxP3, CD68, CD20, CD57, Granzyme B (GzmB), PD-1, and PD-L1. Area under the curve (AUC) was calculated using Ripley’s L function, which evaluates the degree of spatial proximity of two cell populations, with a high AUC indicating clustering and low AUC indicating scattering. Findings were integrated with clinical parameters. Results Adenocarcinomas demonstrated CD3+PD1+ T cells were closer to CK+ tumor cells (n=60, p=0.035), and B cells were closer to cytotoxic T cells (n=43, p=0.03) than in squamous cell carcinoma. Higher AUC was observed between CD3+PD1+ T cells (n=56, p=0.035), with cytotoxic antigen-experienced T cells (CD45RO+GzmB+) closer to tumor cells (n=35, p=0.017) in stage I and II compared to stage III tumors. Untreated patient tumors exhibited higher proximity between CD20+ B cells and CD57+ NK cells (n=59, p=0.012), CD3+ T cells and PD-L1+ tumor cells (n=56, p=0.027), and CD68+ macrophages and PD-L1+ tumor cells (n=52, p=0.016) than neoadjuvant chemotherapy-treated patients. Patients with no recurrence presented higher AUC in antigen-experienced CD45RO+GzmB+ T cells and tumor cells (n=36, p=0.006), while those with improved survival demonstrated greater proximity between CD68+ macrophages and PD-L1+ tumors (n=52, p=0.016), CD20+ B cells and GzmB+ cells (n=49, p=0.03), and antigen-experienced CD45RO+GzmB+ T cells and tumor cells (n=36, p=0.047). Lastly, patients with improved survival also displayed greater proximity between CD3+CD8+ cytotoxic T cells and PD-L1- epithelial cells (n=76, p=0.04) in tumors versus matched adjacent lungs. Conclusions Overall, our findings shed light on some of the potential cell interactions at play in the tumor microenvironment of early-stage NSCLC patients and suggest cell distributions could be utilized to predict clinical outcomes in early-stage NSCLC patients.
Antiphospholipid Antibody Profiles and Thrombotic Outcomes in the Starlet Cohort of Patients with Systemic Lupus Erythematosus
Authors: Alistair Murray, Eric J. Campbell, Ann E. Clarke, Megan R.W. Barber, Tania Pannu, Marvin J. Fritzler, Michelle Jung, Yvan St. Pierre, Leslie Skeith
Journal: Blood (2021)
Multi-Center, Multi-Vendor Reproducibility and Calibration of MRI-Based R2* for Liver Iron Quantification
Authors: Diego Hernando, Ruiyang Zhao, Qing Yuan, Mounes Aliyari Ghasabeh, Stefan Ruschke, Xinran Miao, Dimitrios C. Karampinos, Lu Mao, David T. Harris, Ryan J. Mattison, Michael R. Jeng, Ivan Pedrosa, Ihab R. Kamel, Shreyas Vasanawala, Takeshi Yokoo, Scott B. Reeder
Journal: Blood (2021)
Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome
Authors: Christopher N Hahn, Simone K. Feurstein, Deepak Singhal, Monika M Kutyna, Rakchha Chhetri, Amilia Wee, Daniel Thomas, Hamish S Scott, Devendra Hiwase
Journal: Blood (2021)
Prevalence of High BMI Status in Adults with Sickle Cell Disease
Authors: Stephanie O Ibemere, Laura Niederer, Charity I Oyedeji, Ebony Burns, John Myers, Liliana Preiss, Robert Ward Hagar, Cathy L Melvin, Allison A. King, Jeffrey Glassberg, Angela B Snyder, Melissa Azul, Jane S Hankins, Faiz Ahmed Hussain, Paula Tanabe, Nirmish Shah
Journal: Blood (2021)